“Project BioShield”: Industry Has Concerns, FDA Offers Support
Executive Summary
A "Project BioShield" provision that would allow government funding only for bioterrorism countermeasures for which no commercial market exists is understood to be a concern among pharmaceutical and biotech companies
You may also be interested in...
BioShield House Compromise Could Serve As Template For Senate
The House Energy & Commerce Committee and White House funding compromise for Project BioShield could serve as a template for agreement in the Senate
BioShield House Compromise Could Serve As Template For Senate
The House Energy & Commerce Committee and White House funding compromise for Project BioShield could serve as a template for agreement in the Senate
PhRMA Urges Antitrust Exemption For Bioterrorism Research
An antitrust exemption to allow pharmaceutical companies to share production techniques for bioterrorism countermeasures will speed development of necessary agents, the Pharmaceutical Research & Manufacturers of America says